THE ROLE OF SILDENAFIL IN MODERATE TO SEVERE CF LUNG DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是一项小型研究，目的是了解西地那非在减少囊性纤维化炎症方面是否安全有效。 慢性肺囊炎肺部疾病的发生部分是因为细菌感染，以及身体对抗感染的反应[称为炎症]。一些用于治疗慢性肺病的药物旨在减轻这种炎症。实验室的研究人员已经证明，用西地那非处理的CF细胞的炎症和感染都有所减少。目前尚不清楚使用西地那非治疗CF患者是否也会减少炎症和感染。本研究的目的是确定西地那非治疗CF患者是否能减轻炎症。我们还将测试它是否能让CF患者感觉更好，并允许他们进行更多运动。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is a small study being done to see if sildenafil is safe and effective in decreasing inflammation in cystic fibrosis [CF]. Lung disease in CF develops in part because of bacterial infection, and the body's response to fight the infection [called inflammation]. Some of the medications used to treat CF lung disease are aimed at decreasing this inflammation. Researchers in laboratories have shown that inflammation and infection are decreased in CF cells that are treated with sildenafil. It is not known if treating CF patients with sildenafil will also decrease inflammation and infection. The purpose of this study is to determine if treating CF patients with sildenafil decreases inflammation. We will also test whether it makes CF patients feel better and allows them to exercise more.